Table 6 In vitro cytotoxic screening of 5a–n against MDA-MB-231 human breast cancer cells
Comp. | Validity (%) for sample concentrations (µg/mL) | IC50 (µg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 10 | 31.25 | 62.5 | 125 | 250 | 500 | ||
5a | 100 | 98.3 | 96.7 | 93.6 | 86.1 | 85.9 | 82.5 | 75.8 | 1498 |
5b | 100 | 97.8 | 97.4 | 90.8 | 88.6 | 87.3 | 83.6 | 81.5 | 1625 |
5c | 100 | 97.1 | 95.7 | 95.8 | 92.1 | 86.3 | 84.5 | 83.04 | 1690 |
5d | 100 | 96.8 | 94.4 | 93.7 | 92.4 | 88.4 | 87.2 | 85.7 | 1740 |
5e | 100 | 97.3 | 96.3 | 93.6 | 92.6 | 85.5 | 75.9 | 73.7 | 1405 |
5f | 100 | 98.1 | 97.2 | 88.95 | 84.7 | 81.03 | 79.6 | 77.5 | 1540 |
5g | 100 | 92.6 | 87.3 | 80.9 | 72.2 | 67.7 | 63.2 | 58.5 | 525 |
5h | 100 | 90.9 | 82.8 | 79.3 | 76.8 | 71.7 | 61.7 | 56.7 | 514 |
5i | 100 | 96.00 | 83.8 | 61.00 | 56.2 | 52.2 | 50.5 | 46.1 | 334 |
5j | 100 | 94.4 | 74.8 | 66.99 | 61.4 | 60.2 | 57.2 | 49.3 | 435 |
5k | 100 | 92.3 | 85.8 | 68.7 | 60.8 | 56.7 | 50.6 | 42.98 | 330 |
5l | 100 | 99.11 | 87.6 | 79.7 | 76.2 | 72.4 | 64.6 | 57.8 | 522 |
5m | 100 | 97.3 | 89.5 | 85.4 | 88.3 | 76.9 | 65.6 | 50.6 | 505 |
5n | 100 | 98.7 | 91.0 | 92.8 | 90.6 | 76.8 | 58.7 | 27.2 | 315 |